We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
What do we know about the cardiac valve lesion in the antiphospholipid syndrome (APS)?
- Authors
Amigo, M-C
- Abstract
Heart valve disease (HVD) is the most common cardiac manifestation in the antiphospholipid syndrome (APS). Valve lesions should be described according to the established definition. HVD is progressive despite anticoagulant/antiplatelet treatments. Around 4–6% of patients with HVD in APS will require valve replacement surgery, which is considered a very high risk procedure in APS. Unfortunately, no recommendations regarding medical treatment of antiphospholipid antibodies-associated HVD can be made at this moment. There are evidence-based data and strong pathophysiologic rationale for considering HVD as a manifestation of APS. Thus, HVD should be included as a criterion of definite APS.
- Subjects
ANTIPHOSPHOLIPID syndrome; ANTIPHOSPHOLIPID syndrome treatment; PLATELET aggregation inhibitors; ANTICOAGULANTS; PHOSPHOLIPID antibodies; SYMPTOMS; DIAGNOSIS
- Publication
Lupus, 2014, Vol 23, Issue 12, p1259
- ISSN
0961-2033
- Publication type
Article
- DOI
10.1177/0961203314534307